Format

Send to

Choose Destination
See comment in PubMed Commons below
Neurol Sci. 2008 Sep;29 Suppl 2:S230-2. doi: 10.1007/s10072-008-0946-x.

Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis.

Author information

1
Centro Studi Sclerosi Multipla, Gallarate, Italy. mauro.zaffaroni@aogallarate.it

Abstract

We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-beta (IFN-beta) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-beta (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset.

PMID:
18690501
DOI:
10.1007/s10072-008-0946-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center